Delivery Order SPE2DB20D3103-SPE2DB25FP0B9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 6, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units, with a ceiling value of $6,576.04 and an ultimate completion date of May 7, 2025. This is a firm fixed price delivery order with no set-aside designation, competed through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units, with a ceiling value of $5,969.33. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 8, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the vendor's demonstrated capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30-tablet units, with a contract ceiling value of $13,740.06. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract is scheduled for ultimate completion on September 12, 2025, and will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on May 7, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This $5,118.27 firm fixed price delivery order, with a completion date of May 8, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The award was made through open competition with no set-aside designation, and the pharmaceutical products will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units, with a ceiling value of $5,651.30. This is a firm fixed-price delivery order with a completion deadline of September 12, 2025, and represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30-count units, with a contract ceiling value of $117,392.05. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, with an ultimate completion date of June 3, 2025....
- The Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $12,570.58, represents a non-competitive, non-set-aside procurement and is scheduled for completion by August 26, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $3,198.50, was competitively awarded without set-aside designation and is scheduled for completion by August 22, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $8,141.67, represents a non-competitive set-aside procurement and is scheduled for ultimate completion by August 1, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $46,224.65 for Xeljanz XR 11 mg tablets (30-count unit of use packaging) on April 24, 2025, with completion scheduled for April 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's ongoing supply of pharmaceutical products to federal medical procurement needs. The place of performance is...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP0B9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $46,432.78 and is scheduled for completion by June 2, 2025. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete in open federal procurement. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor for federal military and healthcare systems, AmerisourceBergen supplies an extensive portfolio of branded and generic medications, vaccines, and medical supplies to support Defense Health Agency and other federal healthcare programs worldwide. The company's federal contract history demonstrates consistent capability in fulfilling diverse pharmaceutical procurement requirements across multiple therapeutic domains through firm fixed-price delivery orders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.4k | 5/30/25 |